Genmab stock holds on to late-stage data momentum
Published on 07/20/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab stock stays tied to a business that delivered DKK 19.6 billion in revenue in 2024, up from DKK 14.4 billion in 2023, while operating profit reached DKK 6.2 billion for the year, according to the company’s 2024 annual report. The Danish biotech company (ISIN DK0010272202) also reported DKK 11.7 billion in net profit for 2024, which gives the shares a clear earnings base beyond pipeline headlines.
Revenue reached DKK 19.6 billion
The annual report shows a 36% rise in revenue year on year, from DKK 14.4 billion in 2023 to DKK 19.6 billion in 2024, driven by commercial demand and royalties. That comparison matters because Genmab’s valuation depends on whether product sales and royalties can keep scaling faster than development spending.
Operating profit moved to DKK 6.2 billion in 2024 from DKK 3.7 billion in 2023, while net profit increased to DKK 11.7 billion from DKK 7.7 billion, according to the same report. The gap between top-line growth and profit growth shows how important royalty income and cost control remain for the company’s earnings profile.
Profit rose faster than sales
Genmab’s 2024 net profit margin was about 60%, calculated from DKK 11.7 billion in profit on DKK 19.6 billion in revenue. That is an unusually high level for a biotech company and reflects the leverage created by antibody royalties and an expanding commercial footprint.
The company said its 2024 results also came with DKK 17.8 billion in cash and cash equivalents at year-end. For investors, that cash position matters because it supports late-stage development, business development and shareholder flexibility without immediate financing pressure.
Pipeline still drives the story
Darzalex remains the most visible product linked to Genmab’s economics, because the company earns royalties on sales of the multiple myeloma therapy. Genmab has also built relevance around its partnered antibody platform, which keeps the pipeline and royalty stream connected rather than separate.
The market usually focuses on whether Genmab can turn one strong commercial asset into a broader earnings base. A year like 2024, with DKK 19.6 billion in revenue and DKK 6.2 billion in operating profit, gives that debate more weight than a pure research narrative.
Cash and valuation focus
Because no dated live quote is available in the current source set, the clearest market marker here is the 2024 financial base rather than a same-day price. Genmab’s reported DKK 17.8 billion cash balance and DKK 11.7 billion net profit remain the numbers most likely to frame any fresh re-rating discussion.
As a result, Genmab stock now trades more like a profitable oncology platform than a development-stage story. The next question is whether the company can extend its royalty-led earnings into another year of double-digit revenue growth.
Darzalex still matters
Darzalex is the product that best explains Genmab’s commercial scale, because royalties from the therapy continue to anchor its income profile. The product line matters not only for sales visibility but also because it supports the company’s broader antibody strategy.
Genmab stock at a glance
Genmab stock is still defined by a mix of royalties, late-stage development and a strong cash position, with 2024 revenue of DKK 19.6 billion, operating profit of DKK 6.2 billion and net profit of DKK 11.7 billion. Those figures, together with DKK 17.8 billion in cash and cash equivalents at year-end 2024, are the most relevant anchors for assessing the shares today.
Genmab stock key facts
- Company: Genmab A/S
- ISIN: DK0010272202
- Ticker: CPH: GMAB
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Biotechnology
- Index membership: OMX Copenhagen 25
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
